Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Jun 21;19(1):612.
doi: 10.1186/s12885-019-5846-3.

Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study

Kerri Beckmann  1   2 , Beth Russell  3 , Debra Josephs  3 , Hans Garmo  3   4 , Christel Haggstrom  5   6 , Lars Holmberg  3   6 , Pär Stattin  6 , Mieke Van Hemelrijck  3   7 , Jan Adolfsson  8
Affiliations
Observational Study

Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study

Kerri Beckmann et al. BMC Cancer. .

Abstract

Background: Whether chronic inflammation increases prostate cancer risk remains unclear. This study investigated whether chronic inflammatory diseases (CID) or anti-inflammatory medication use (AIM) were associated with prostate cancer risk.

Methods: Fifty-five thousand nine hundred thirty-seven cases (all prostate cancer, 2007-2012) and 279,618 age-matched controls were selected from the Prostate Cancer Database Sweden. CIDs and AIMs was determined from national patient and drug registers. Associations were investigated using conditional logistic regression, including for disease/drug subtypes and exposure length/dose.

Results: Men with a history of any CID had slightly increased risk of any prostate cancer diagnosis (OR: 1.08; 95%CI: 1.04-1.12) but not 'unfavourable' (high-risk or advanced) prostate cancer. Generally, risk of prostate cancer was highest for shorter exposure times. However, a positive association was observed for asthma > 5 years before prostate cancer diagnosis (OR: 1.21; 95%CI: 1.05-1.40). Risk of prostate cancer was increased with prior use of any AIMs (OR: 1.26; 95%CI: 1.24-1.29). A positive trend with increasing cumulative dose was only observed for inhaled glucocorticoids (p < 0.011).

Conclusion: Detection bias most likely explains the elevated risk of prostate cancer with prior history of CIDs or use of AIMs, given the higher risk immediately after first CID event and lack of dose response. However, findings for length of time with asthma and dose of inhaled glucocorticoids suggest that asthma may increase risk of prostate cancer through other pathways.

Keywords: Anti-inflammatory medication; Autoimmune disease; Chronic inflammatory disease; Prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Shacter E, Weitzman SA: Chronic inflammation and cancer. Oncology (Williston Park) 2002, 16(2):217–226, 229; discussion 230-212. - PubMed
    1. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 2012;60(1):199–215. doi: 10.1111/j.1365-2559.2011.04033.x. - DOI - PMC - PubMed
    1. Vasto S, Carruba G, Candore G, Italiano E, Di Bona D, Caruso C. Inflammation and prostate cancer. Future Oncol. 2008;4(5):637–645. doi: 10.2217/14796694.4.5.637. - DOI - PubMed
    1. Sutcliffe S, Platz EA. Inflammation in the etiology of prostate cancer: an epidemiologic perspective. Urol Oncol. 2007;25(3):242–249. doi: 10.1016/j.urolonc.2006.09.014. - DOI - PubMed
    1. Sfanos KS, Hempel HA, De Marzo AM. The role of inflammation in prostate cancer. Adv Exp Med Biol. 2014;816:153–181. doi: 10.1007/978-3-0348-0837-8_7. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources